Cargando…

Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer

PURPOSE: We sought to exploit the heterogeneity afforded by patient-derived tumor xenografts (PDX) to first, optimize and identify robust radiomic features to predict response to therapy in subtype-matched triple negative breast cancer (TNBC) PDX, and second, to implement PDX-optimized image feature...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roy, Sudipta, Whitehead, Timothy D., Li, Shunqiang, Ademuyiwa, Foluso O., Wahl, Richard L., Dehdashti, Farrokh, Shoghi, Kooresh I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800941/ https://www.ncbi.nlm.nih.gov/pubmed/34328530 http://dx.doi.org/10.1007/s00259-021-05489-8

Ejemplares similares

Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
por: Roy, Sudipta, et al.
Publicado: (2021)

Optimal co-clinical radiomics: Sensitivity of radiomic features to tumour volume, image noise and resolution in co-clinical T1-weighted and T2-weighted magnetic resonance imaging
por: Roy, Sudipta, et al.
Publicado: (2020)

Deep Learning Segmentation of Triple-Negative Breast Cancer (TNBC) Patient Derived Tumor Xenograft (PDX) and Sensitivity of Radiomic Pipeline to Tumor Probability Boundary
por: Dutta, Kaushik, et al.
Publicado: (2021)

Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database
por: Bagegni, Nusayba A., et al.
Publicado: (2019)

Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2013)

Measurement Repeatability of (18)F-FDG PET/CT Versus (18)F-FDG PET/MRI in Solid Tumors of the Pelvis
por: Fraum, Tyler J., et al.
Publicado: (2019)

Multiparametric (18)F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
por: Umutlu, Lale, et al.
Publicado: (2022)

Test–Retest Performance of a 1-Hour Multiparametric MR Image Acquisition Pipeline With Orthotopic Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts
por: Ge, Xia, et al.
Publicado: (2019)

Pilot Study: PARP1 Imaging in Advanced Prostate Cancer
por: Dehdashti, Farrokh, et al.
Publicado: (2022)

Extensive Metastatic Sarcomatoid Renal Cell Carcinoma Evaluated by (18)F-FDG PET/CT: a Case Report and Review of Literature
por: Fuser, Dominique, et al.
Publicado: (2018)

Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent
por: Marquez-Nostra, Bernadette V., et al.
Publicado: (2017)

Metabolic Radiomics for Pretreatment (18)F-FDG PET/CT to Characterize Locally Advanced Breast Cancer: Histopathologic Characteristics, Response to Neoadjuvant Chemotherapy, and Prognosis
por: Ha, Seunggyun, et al.
Publicado: (2017)

Development and External Validation of (18)F-FDG PET-Based Radiomic Model for Predicting Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer
por: Lim, Chae Hong, et al.
Publicado: (2023)

Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL
por: Mazzara, Saveria, et al.
Publicado: (2022)

In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [(18)F]FDG and [(64)Cu]Cu-LLP2A PET
por: Ghai, Anchal, et al.
Publicado: (2021)

The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas
por: Palmerini, Emanuela, et al.
Publicado: (2016)

First-in-Humans Evaluation of Safety and Dosimetry of (64)Cu-LLP2A for PET Imaging
por: Laforest, Richard, et al.
Publicado: (2023)

Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins
por: Wang, Junkai, et al.
Publicado: (2023)

A Simultaneous Multiparametric (18)F-FDG PET/MRI Radiomics Model for the Diagnosis of Triple Negative Breast Cancer
por: Romeo, Valeria, et al.
Publicado: (2022)

External validation of (18)F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy
por: Valkema, Maria J., et al.
Publicado: (2023)

PET/CT-based radiomics analysis may help to predict neoadjuvant chemotherapy outcomes in breast cancer
por: Yang, Liping, et al.
Publicado: (2022)

Value of [(18)F]FDG PET/CT radiomic parameters in the context of response to chemotherapy in advanced cervical cancer
por: Burchardt, Ewa, et al.
Publicado: (2023)

In Vivo Multi-Tissue Efficacy of Peroxisome Proliferator-Activated Receptor-γ Therapy on Glucose and Fatty Acid Metabolism in Obese Type 2 Diabetic Rats
por: Nemanich, Samuel, et al.
Publicado: (2013)

[(18)F]FDG PET Immunotherapy Radiomics Signature (iRADIOMICS) Predicts Response of Non-small-cell Lung Cancer Patients Treated with Pembrolizumab
por: Valentinuzzi, Damijan, et al.
Publicado: (2020)

Prediction of Non-Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients with (18)F-FDG PET Radiomics Based Machine Learning Classification
por: Beukinga, Roelof J., et al.
Publicado: (2022)

A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck
por: Adkins, Douglas, et al.
Publicado: (2014)

(18)F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma
por: Kong, Ziren, et al.
Publicado: (2019)

Prognostic value of FDG-PET radiomics with machine learning in pancreatic cancer
por: Toyama, Yoshitaka, et al.
Publicado: (2020)

The Impact of Artificial Intelligence CNN Based Denoising on FDG PET Radiomics
por: Jaudet, Cyril, et al.
Publicado: (2021)

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
por: Keam, Bhumsuk, et al.
Publicado: (2011)

FDG-PET/CT lymph node staging after neoadjuvant chemotherapy in patients with adenocarcinoma of the esophageal–gastric junction
por: Fencl, Pavel, et al.
Publicado: (2016)

Prediction of pathological response after neoadjuvant chemotherapy using baseline FDG PET heterogeneity features in breast cancer
por: Oliveira, Carla, et al.
Publicado: (2023)

Galuminox: Preclinical validation of a novel PET tracer for non-invasive imaging of oxidative stress in vivo
por: Sivapackiam, Jothilingam, et al.
Publicado: (2020)

Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab
por: Bagegni, Nusayba A, et al.
Publicado: (2022)

A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients
por: Zheng, Tianzhi, et al.
Publicado: (2019)

Gene signature‐based prediction of triple‐negative breast cancer patient response to Neoadjuvant chemotherapy
por: Zhao, Yanding, et al.
Publicado: (2020)

Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Omar, Mohamed, et al.
Publicado: (2023)

A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation
por: Li, Yimin, et al.
Publicado: (2020)

Predictive Power of a Radiomic Signature Based on (18)F-FDG PET/CT Images for EGFR Mutational Status in NSCLC
por: Li, Xiaofeng, et al.
Publicado: (2019)

Predicting MYCN amplification in paediatric neuroblastoma: development and validation of a 18F-FDG PET/CT-based radiomics signature
por: Qian, Luo-Dan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fd8t3g03q8a267kp0ra0uuo0fo